Cameron Durrant, MD, MBA

Chairman & CEO

  • Serial biotech experience as CEO, CFO, Chair, Exec Chair

  • Merck, GSK, Pharmacia, J+J

  • Launched 5 blockbusters during career, including antivirals

Timothy Morris, CPA

Chief Operating and Financial Officer

  • Over 36 years of professional finance and accounting experience

  • Over 22 years as Chief Financial Officer with public biotechnology companies (IOVA, ACRX, VVUS, QCOR)

  • Raised over $2 billion in equity and convertible securities for seven companies, completed four offerings for IOVA with over $1 billion in proceeds

  • Oversaw increase in market cap of Iovance Biotherapeutics from $550 million to $4.2 billion (7x increase)

  • Extensive deal experience with over 75 transactions and combined value in excess of $4 billion

Bob Atwill, MBA

SVP, Head of Asia-Pacific Region

  • Over 30 years of executive pharma, biotech, cell therapy and healthcare experience

  • Corporate Officer in listed NYSE, NASDAQ, LSE, ASX and in other organisations for over 23-years

  • Expertise in COVID-19, GvHD, virology, I/O and cell & gene therapy

  • GSK, Sanofi-Synthélabo, Mesoblast and Benitec Biopharma

  • APAC based cross-border M&A and capital service principal with Eaton Square

Edward P. Jordan, MBA
Chief Commercial Officer 

  • Over 20 years experience building and leading commercial organizations

  • Broad commercial experience spanning many therapeutic areas

  • Biotech builder with biologic experience

  • Extensive launch experience and builder of new therapeutic markets

  • DBV Technologies, AMAG, TEVA, Schering-Plough

Dale Chappell, MD, MBA

Chief Scientific Officer

  • Founder, Black Horse Capital Advisors

  • Decades of biotechnology investment experience

  • HHMI Fellow, National Cancer Institute, Rosenberg Lab

  • Multiple publications in T-cell therapy, GM-CSF and immunology pathways

David Tousley, MBA, CPA

Chief Accounting and Administrative Officer,

Corp Secretary and Treasurer

  • Significant Pharma and Biotech experience, President, COO, CFO

  • Sanofi Pasteur, AVAX Technologies, DARA BioSciences, Peat, Marwick, Mitchell & Co.

  • IPOs, PIPEs, follow-ons, Debt; 

  • Public, Private & international experience

  • Mergers, acquisitions, divestitures, partnerships and JVs in U.S. and internationally


Omar Ahmed, PharmD

SVP, Clinical, Medical and Scientific Affairs

  • ​20-year pharmaceutical executive at Roche, Novartis, J&J

  • Led multiple blockbuster launches setting a new SOC globally

  • Led development of Janssen’s immunology portfolio strategy

  • Deep expertise in I/O and biologics development

  • Led collaborations with GSK, Merck, Astellas, Vertex, Idenix, and others ​



Rainer Boehm, M.D., MBA

Cameron Durrant, M.D., MBA

Ronald Barliant, JD

Cheryl Buxton, MA

Dale Chappell M.D., MBA

Follow Us

  • Twitter
  • LinkedIn
  • Facebook

©2021 Humanigen, Inc.  All rights reserved